Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41385-021-00384-9 http://scihub22266oqcxt.onion/10.1038/s41385-021-00384-9 33608656!7893623!33608656     free     free     free       Mucosal+Immunol 2021 ; 14 (3): 566-573 Nephropedia Template TP {{tp|p=33608656|t=2021. COVID-19-from mucosal immunology to IBD patients |pdf=|usr=}}{{33608656}} gab.com Text COVID-19-from mucosal immunology to IBD patients JO: Mucosal Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33608656 #FOAvip Viral infections with SARS-CoV-2 can cause a multi-facetted disease, which is not only characterized by pneumonia and overwhelming systemic inflammatory immune responses, but which can also directly affect the digestive system and infect intestinal epithelial cells. Here, we review the current understanding of intestinal tropism of SARS-CoV-2 infection, its impact on mucosal function and immunology and summarize the effect of immune-suppression in patients with inflammatory bowel disease (IBD) on disease outcome of COVID-19 and discuss IBD-relevant implications for the clinical management of SARS-CoV-2 infected individuals. Twit Text FOAVip COVID-19-from mucosal immunology to IBD patients ????Mucosal Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33608656 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33608656 #FOAvip English Wikipedia <ref>{{Cite pmid|33608656}}</ref> COVID-19-from mucosal immunology to IBD patients #MMPMID33608656 Weidinger C; Hegazy AN; Glauben R; Siegmund B Mucosal Immunol 2021[May]; 14 (3): 566-573 PMID33608656show ga Viral infections with SARS-CoV-2 can cause a multi-facetted disease, which is not only characterized by pneumonia and overwhelming systemic inflammatory immune responses, but which can also directly affect the digestive system and infect intestinal epithelial cells. Here, we review the current understanding of intestinal tropism of SARS-CoV-2 infection, its impact on mucosal function and immunology and summarize the effect of immune-suppression in patients with inflammatory bowel disease (IBD) on disease outcome of COVID-19 and discuss IBD-relevant implications for the clinical management of SARS-CoV-2 infected individuals. |*Immunity, Mucosal[MESH] |Biomarkers[MESH] |COVID-19/*complications/diagnosis/*immunology/virology[MESH] |Host-Pathogen Interactions/*immunology[MESH] |Humans[MESH] |Immunity, Innate[MESH] |Inflammatory Bowel Diseases/*complications/diagnosis/*immunology[MESH] |Intestinal Mucosa/immunology/metabolism/pathology[MESH] |SARS-CoV-2/*physiology[MESH] |Severity of Illness Index[MESH] |Symptom Assessment[MESH] |Viral Tropism[MESH]COVID-19-from mucosal immunology to IBD patients (epmc).pdf DeepDyve Pubget Overpricing